A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Fulacimstat (Primary)
- Indications Diabetic nephropathies
- Focus Biomarker; Therapeutic Use
- Acronyms CADA DIA
- Sponsors Bayer
- 30 Oct 2019 Status changed from active, no longer recruiting to completed.
- 18 Oct 2019 This trial has been completed in Denmark.
- 19 Mar 2019 Planned End Date changed from 23 Sep 2019 to 17 Oct 2019.